Anavar vs Anadrol: Opposite Ends of the Oral Steroid Spectrum Compared by Clinical Data

The Anavar vs Anadrol comparison is the clearest example in AAS pharmacology of how two compounds in the same drug class can produce radically different outcomes. Both are 17-alpha-alkylated oral steroids. Both are FDA-approved for clinical indications. Both produce measurable lean body mass gains in controlled trials. But the similarity ends there. Oxandrolone (Anavar) is the mildest oral steroid by clinical metrics: low liver toxicity, no aromatisation, minimal water retention, and a side effect profile that clinical investigators describe as “well-tolerated.” Oxymetholone (Anadrol) is the most potent oral steroid by the same metrics: the highest incidence of hepatotoxicity among common AAS, significant water retention, profound HDL suppression, and clinical trial dropout rates driven by adverse events. Understanding the Anavar vs Anadrol comparison through their respective clinical data, rather than through forum anecdotes, allows you to choose the compound that matches your specific goal, risk tolerance, and cycle architecture. At Hemi Pharma UK, we carry both compounds because they serve fundamentally different purposes, and selecting the right one requires understanding why they are not interchangeable.

What Does the Liver Toxicity Data Show for Anavar vs Anadrol?

This is the most clinically significant difference between the two compounds, and the data is unambiguous. Oxymetholone is dramatically more hepatotoxic than oxandrolone at their respective clinical doses.

The pivotal oxymetholone hepatotoxicity data comes from Hengge et al. (2003), published in AIDS. In a randomised, double-blind, placebo-controlled trial of 89 HIV-positive patients with wasting, oxymetholone was administered at 100mg or 150mg daily for 16 weeks. ALT rose above 5 times the upper limit of normal in 27% of patients on 100mg daily and 35% of patients on 150mg daily. No patients on placebo developed this degree of transaminase elevation. Serious liver-related adverse events, including jaundice, hepatomegaly, and hyperbilirubinaemia, were documented in the treatment groups (Hengge et al., 2003).

The comprehensive pharmacology review by Pavlatos et al. (2001) in Clinical Therapeutics confirmed that hepatotoxicity is the major adverse effect of oxymetholone, with cholestatic jaundice being the most important hepatic manifestation. The review noted that less common but more severe hepatic complications include peliosis hepatis (blood-filled cavities in the liver parenchyma) and hepatocellular tumours, both of which have been reported in association with prolonged oxymetholone use (Pavlatos et al., 2001).

Compare this to oxandrolone. The Kopel, Sorensen, and Griswold (2022) reappraisal of oxandrolone in burn management reviewed 18 clinical studies and concluded that oxandrolone therapy “did not affect liver function” across the populations studied (Kopel et al., 2022). A 2025 updated meta-analysis of 14 randomised controlled trials (2,822 patients) in the World Journal of Emergency Surgery confirmed that oxandrolone produced no clinically significant hepatic adverse events across the pooled study populations (WJES meta-analysis, 2025).

The magnitude of difference is stark. Oxymetholone at clinical doses produces ALT elevations above 5x ULN in 27 to 35% of patients within 16 weeks. Oxandrolone across 14 RCTs totalling 2,822 patients produced no clinically significant liver function changes. These are not two compounds with slightly different hepatotoxicity profiles. They are at opposite ends of the oral steroid safety spectrum.

How Do the Body Composition Results Compare Between Anavar vs Anadrol in Controlled Trials?

Oxymetholone produces larger absolute gains in body mass, but a substantial proportion of that mass is water. Oxandrolone produces smaller absolute gains, but those gains are compositionally cleaner (more lean tissue, less fluid) and more durable after cessation.

In the Hengge et al. (2003) HIV wasting trial, oxymetholone at 100mg daily produced a mean weight gain of 3.0 to 3.5kg over 16 weeks, with body cell mass increasing by 3.8kg (12.4% of baseline) in the lower-dose group. These are substantial gains in a catabolic population. However, the study also documented significant oedema and fluid retention as contributing factors to the weight gain, and the 16-week duration meant that participants were exposed to the hepatotoxicity risk for a full 4 months.

Oxandrolone data from the Schroeder study (20mg daily for 12 weeks in older men) showed lean body mass increases of approximately 2 to 3kg with simultaneous fat mass reductions of approximately 1.5 to 2kg, with 83% of the fat loss sustained 12 weeks after stopping. The critical difference is in durability and composition: oxandrolone’s lean mass gains are genuine tissue, not fluid, and the fat loss component persists after cessation. Anadrol’s weight gains, by contrast, are substantially fluid-dependent and reverse significantly within weeks of stopping due to the resolution of oedema and glycogen supercompensation.

For bodybuilding applications, this compositional difference defines the use cases completely. Anadrol is a mass-building tool for users who want maximum weight gain and visual size regardless of composition (off-season bulking, pre-competition size loading). Anavar is a body recomposition tool for users who want lean tissue preservation, fat reduction, and a dry aesthetic without fluid accumulation (cutting phases, weight-class sports, and cosmetic refinement).

Which Compound Produces More Water Retention and Why Does the Mechanism Matter?

Oxymetholone produces significant water retention through a mechanism that remains incompletely understood but is clinically well documented. Unlike testosterone, oxymetholone does not aromatise to oestradiol through the standard aromatase pathway. Yet it produces oestrogenic effects (water retention, gynecomastia in some users) that suggest either direct oestrogenic receptor agonism or activation of oestrogenic pathways through non-aromatase mechanisms. Some researchers have proposed that oxymetholone or one of its metabolites may act directly as an oestrogen receptor agonist, bypassing aromatisation entirely.

Oxandrolone produces no water retention. It does not aromatise, it has no known direct oestrogenic activity, and its primary effect on fluid balance is a reduction in subcutaneous water retention through SHBG-mediated hormonal shifts and the absence of oestrogenic signalling. The “dry” appearance that Anavar produces is, in pharmacological terms, the absence of the fluid accumulation that most other AAS produce.

The practical consequence is that Anadrol weight gains look impressive on the scale but are partially reversible (the fluid component dissipates within 1 to 2 weeks of cessation). Anavar weight changes are modest on the scale but represent genuine tissue-level recomposition (muscle gain and fat loss simultaneously) that is more durable. Users who equate scale weight with progress will favour Anadrol. Users who prioritise mirror appearance and lasting compositional change will favour Anavar.

How Do the Side Effect Profiles Compare Beyond the Liver for Anavar vs Anadrol?

HDL suppression

Both compounds suppress HDL as 17-alpha-alkylated oral steroids through hepatic lipase upregulation. The magnitude is severe for both, though Anadrol’s higher hepatic toxicity load may produce more profound lipid derangement at equivalent treatment durations. As covered in our Anavar and cholesterol article, HDL reductions of 50% or more are typical for oral steroids at bodybuilding doses. Neither compound is spared from this effect.

HPTA suppression

Both compounds comprehensively suppress the HPT axis. Oxymetholone, given its higher potency and typical dosing (50mg to 100mg daily versus 30mg to 60mg for Anavar), may produce marginally deeper suppression, but the practical difference is minimal: both require a testosterone base and both require PCT after cessation (as detailed in our Anavar PCT article).

Androgenic effects

Oxymetholone has a higher androgenic rating and produces more pronounced androgenic side effects at bodybuilding doses: more severe acne, greater hair loss acceleration in predisposed individuals, and stronger prostate stimulation. Oxandrolone’s very low androgenic rating (24 versus testosterone’s 100) means these effects are substantially milder, which is why Anavar is preferred for women and for men prioritising hair and skin preservation (as covered in our Anavar and hair loss article).

Blood pressure and cardiovascular stress

Anadrol’s water retention increases blood volume and can produce significant blood pressure elevation. The Pavlatos (2001) review noted oedema as a recognised adverse effect. Oxandrolone does not produce water retention and has a more neutral blood pressure profile, though the HDL suppression from both compounds increases cardiovascular risk through a lipid pathway rather than a haemodynamic one.

When Should You Choose Anavar and When Should You Choose Anadrol?

The decision is determined by your primary goal and your risk tolerance:

Choose Anavar when: your goal is cutting, body recomposition, or a dry aesthetic; you want clinically validated safety with minimal liver risk; you are a woman (Anadrol is not suitable for female use due to its high androgenic load); you are on TRT and want a mild oral blast (as covered in our Anavar on TRT article); your cycle length will be 6 to 8 weeks; you prioritise durable compositional changes over scale weight.

Choose Anadrol when: your goal is maximum mass gain during a bulking phase; you accept the higher liver toxicity in exchange for greater anabolic potency; you will limit the cycle to 4 to 6 weeks to manage hepatic exposure (shorter than typical Anavar cycles because of the higher toxicity); you have robust baseline liver function confirmed by pre-cycle bloodwork; you are prepared for significant water retention and the partial reversal of weight gains after cessation.

Some advanced protocols use both compounds in sequence rather than simultaneously. An Anadrol kickstart (4 weeks at 50mg daily to produce rapid mass gains) followed by a transition to Anavar (6 weeks at 40mg daily for body recomposition and hardening) alongside a testosterone base captures the strength of each compound while limiting total hepatic exposure from any single oral. This approach requires a gap of at least 1 to 2 weeks between the two orals to allow partial hepatic recovery, and mid-cycle liver function testing is non-negotiable.

Frequently Asked Questions

Is Anavar or Anadrol better for beginners?

Anavar, by a large margin. The hepatotoxicity data alone settles this: oxymetholone produces ALT elevations above 5x ULN in 27 to 35% of users in controlled trials, while oxandrolone across 14 RCTs totalling 2,822 patients produced no clinically significant liver function changes. For a first oral steroid experience, the milder, better-tolerated compound with the more predictable side effect profile is always the rational choice.

Can I stack Anavar and Anadrol together?

Running two 17-alpha-alkylated oral steroids simultaneously is strongly discouraged. The compounded hepatic load doubles the hepatotoxic exposure, and the additive HDL suppression from dual hepatic lipase activation is severe. If you want elements of both compounds, use them sequentially (Anadrol first for mass, Anavar second for recomposition) with a gap between them, rather than concurrently.

Which gains are more keepable: Anavar or Anadrol?

Anavar’s gains are more durable. The lean mass and fat loss from oxandrolone represent genuine tissue-level changes that persist after cessation (83% fat loss retention at 12 weeks post-treatment in controlled data). Anadrol’s gains include a substantial fluid component that reverses within 1 to 2 weeks of stopping. The net “keepable” tissue gain from Anadrol may be comparable to Anavar’s in absolute terms, but the visual and scale-weight change is far more dramatic during the cycle and far more disappointing after it.

Does Anadrol aromatise if it causes water retention?

Oxymetholone does not aromatise through the standard aromatase enzyme pathway. Its oestrogenic effects (water retention, potential gynecomastia) are believed to result from direct oestrogen receptor activation by the compound or its metabolites, bypassing aromatase entirely. This means aromatase inhibitors such as anastrozole are ineffective at controlling Anadrol’s oestrogenic side effects. Anti-oestrogens such as tamoxifen, which block the oestrogen receptor directly, are the pharmacologically appropriate intervention if oestrogenic symptoms occur during Anadrol use.

Is Anadrol more effective than Anavar for strength?

At equivalent bodybuilding doses, Anadrol produces greater absolute strength gains, driven by both its higher androgenic potency and its fluid-mediated joint lubrication and muscle volumisation. However, much of Anadrol’s strength advantage is drug-dependent: when you stop, the fluid drains, the joint cushioning disappears, and a proportion of the strength gain reverses. Anavar’s strength gains, while more modest, are built on creatine phosphate resynthesis and neuromuscular efficiency improvements that are partially retained after cessation (as covered in our Anavar for strength article). For weight-class athletes who need strength without bodyweight gain, Anavar is categorically superior.